Please select a Capability in order to start your service request.
V. Mueller Bipolar Instruments Promote Improved Safety for Electrosurgical ProceduresMar 6, 2014
SAN DIEGO,CA, March 6, 2014 /PRNewswire/ – CareFusion (NYSE:CFN), a leading global medical technology company, today announced the global launch of a new line of electrosurgical instruments under the V. Mueller® brand.
The new V. Mueller line of bipolar electrosurgical instruments will include both forceps and scissors with approximately 200 options including non-stick, titanium and irrigating options to meet the specific requirements of surgeons. Industry trends indicate that surgeons are migrating to bipolar electrosurgery, because it causes less thermal damage to nearby tissue compared to monopolar instruments.
“Expanding our electrosurgical line to include enhanced bipolar options is good for both our customers and their patients,” said Andreas Lex, vice president and general manager for V. Mueller and Snowden-Pencer® surgical instruments for CareFusion. “V. Mueller has been a trusted name in surgical instruments for decades, and the new line reinforces our commitment to innovation for today’s modern surgeries.”
A key feature of the new scissors in this line is a single-point connection to the electrical source, which reduces the number of wires attached to the handles to improve maneuverability and ease-of-use.
The new instruments are available for product demonstration and evaluation this month.
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of healthcare by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for healthcare providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to healthcare. In 2017, BD welcomed C. R. Bard and its products into the BD family. For more information on BD, please visit bd.com
For more information on BD, please visit bd.com.